Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Cancer Care Northwest - Spokane South
mi
from
Spokane, WA
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Cancer Care Northwest - Spokane South
mi
from
Spokane, WA
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Southwest Washington Medical Center Cancer Center
mi
from
Vancouver, WA
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Southwest Washington Medical Center Cancer Center
mi
from
Vancouver, WA
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Northwest Cancer Specialists at Vancouver Cancer Center
mi
from
Vancouver, WA
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Northwest Cancer Specialists at Vancouver Cancer Center
mi
from
Vancouver, WA
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Wenatchee Valley Medical Center
mi
from
Wenatchee, WA
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Wenatchee Valley Medical Center
mi
from
Wenatchee, WA
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Rocky Mountain Oncology
mi
from
Casper, WY
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Rocky Mountain Oncology
mi
from
Casper, WY
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Welch Cancer Center
mi
from
Sheridan, WY
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Welch Cancer Center
mi
from
Sheridan, WY
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
Status: Archived
Clinical Trial Facility
mi
from
Peoria, AZ
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Peoria, AZ
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
Status: Archived
Clinical Trial Facility
mi
from
Santa Clara, CA
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Santa Clara, CA
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
Status: Archived
Clinical Trial Facility
mi
from
Henderson, NV
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Henderson, NV
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
Status: Archived
Clinical Trial Facility
mi
from
Lebanon, NH
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Lebanon, NH
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
Status: Archived
Clinical Trial Facility
mi
from
Albany, NY
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Albany, NY
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
Status: Archived
Clinical Trial Facility
mi
from
Charleston, SC
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Charleston, SC
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
Status: Archived
Clinical Trial Facility
mi
from
Austin, TX
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Austin, TX
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
Status: Archived
Clinical Trial Facility
mi
from
Richmond, VA
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Richmond, VA
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
Status: Archived
Clinical Trial Facility
mi
from
Mountlake Terrace, WA
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Mountlake Terrace, WA
Temsirolimus and Radiation for Non-Small Cell Lung Cancer
A Phase I Study of Temsirolimus and Thoracic Radiation in Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Washington University
mi
from
St. Louis, MO
Temsirolimus and Radiation for Non-Small Cell Lung Cancer
A Phase I Study of Temsirolimus and Thoracic Radiation in Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Washington University
mi
from
St. Louis, MO
Rollover Protocol for Prior SU011248 Protocols
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol
Status: Archived
Pfizer Investigational Site
mi
from
Alabaster, AL
Rollover Protocol for Prior SU011248 Protocols
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Alabaster, AL
Rollover Protocol for Prior SU011248 Protocols
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol
Status: Archived
Pfizer Investigational Site
mi
from
Los Angeles, CA
Rollover Protocol for Prior SU011248 Protocols
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Los Angeles, CA
Rollover Protocol for Prior SU011248 Protocols
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol
Status: Archived
Pfizer Investigational Site
mi
from
Arvada, CO
Rollover Protocol for Prior SU011248 Protocols
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Arvada, CO
Rollover Protocol for Prior SU011248 Protocols
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol
Status: Archived
Pfizer Investigational Site
mi
from
Avon, IN
Rollover Protocol for Prior SU011248 Protocols
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Avon, IN
Rollover Protocol for Prior SU011248 Protocols
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol
Status: Archived
Darien Pediatric Associates
mi
from
Darien, CT
Rollover Protocol for Prior SU011248 Protocols
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol
Status: Archived
Updated: 1/1/1970
Darien Pediatric Associates
mi
from
Darien, CT
Rollover Protocol for Prior SU011248 Protocols
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol
Status: Archived
Maine Research Associates
mi
from
Auburn, ME
Rollover Protocol for Prior SU011248 Protocols
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol
Status: Archived
Updated: 1/1/1970
Maine Research Associates
mi
from
Auburn, ME
Rollover Protocol for Prior SU011248 Protocols
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol
Status: Archived
Pfizer Investigational Site
mi
from
Duluth, MN
Rollover Protocol for Prior SU011248 Protocols
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Duluth, MN
Rollover Protocol for Prior SU011248 Protocols
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol
Status: Archived
Pfizer Investigational Site
mi
from
Cape Girardeau, MO
Rollover Protocol for Prior SU011248 Protocols
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Cape Girardeau, MO
Rollover Protocol for Prior SU011248 Protocols
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol
Status: Archived
Pfizer Investigational Site
mi
from
Albuquerque, NM
Rollover Protocol for Prior SU011248 Protocols
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Albuquerque, NM
Rollover Protocol for Prior SU011248 Protocols
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
Rollover Protocol for Prior SU011248 Protocols
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
Rollover Protocol for Prior SU011248 Protocols
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol
Status: Archived
Pfizer Investigational Site
mi
from
Asheville, NC
Rollover Protocol for Prior SU011248 Protocols
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Asheville, NC
Rollover Protocol for Prior SU011248 Protocols
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol
Status: Archived
Pfizer Investigational Site
mi
from
Akron, OH
Rollover Protocol for Prior SU011248 Protocols
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Akron, OH
Rollover Protocol for Prior SU011248 Protocols
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol
Status: Archived
Fletcher Allen Health Care
mi
from
Burlington, VT
Rollover Protocol for Prior SU011248 Protocols
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol
Status: Archived
Updated: 1/1/1970
Fletcher Allen Health Care
mi
from
Burlington, VT
Rollover Protocol for Prior SU011248 Protocols
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol
Status: Archived
Pfizer Investigational Site
mi
from
Anderson, SC
Rollover Protocol for Prior SU011248 Protocols
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Anderson, SC
Rollover Protocol for Prior SU011248 Protocols
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol
Status: Archived
Pfizer Investigational Site
mi
from
Bristol, TN
Rollover Protocol for Prior SU011248 Protocols
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Bristol, TN
Rollover Protocol for Prior SU011248 Protocols
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol
Status: Archived
Pfizer Investigational Site
mi
from
Houston, TX
Rollover Protocol for Prior SU011248 Protocols
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Houston, TX
Rollover Protocol for Prior SU011248 Protocols
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol
Status: Archived
Pfizer Investigational Site
mi
from
Madison, WI
Rollover Protocol for Prior SU011248 Protocols
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Madison, WI
COG Registry - Childhood Cancer Research Network (CCRN)
Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN)
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
COG Registry - Childhood Cancer Research Network (CCRN)
Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN)
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Change in Penile Length Following Bilateral Nerve-Sparing Radical Prostatectomy
Assessing the Change in Penile Length Following Bilateral Nerve-Sparing Radical Prostatectomy
Status: Archived
Memorial Sloan-Kettering Cancer Center - Basking Ridge
mi
from
Basking Ridge, NJ
Change in Penile Length Following Bilateral Nerve-Sparing Radical Prostatectomy
Assessing the Change in Penile Length Following Bilateral Nerve-Sparing Radical Prostatectomy
Status: Archived
Updated: 1/1/1970
Memorial Sloan-Kettering Cancer Center - Basking Ridge
mi
from
Basking Ridge, NJ
Lapatinib and Ixabepilone in Treating Patients With Advanced Solid Tumors
Phase I Study of Lapatinib (GW572016) in Combination With Weekly Ixabepilone (BMS 247550) in Advanced Solid Tumors
Status: Archived
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Lapatinib and Ixabepilone in Treating Patients With Advanced Solid Tumors
Phase I Study of Lapatinib (GW572016) in Combination With Weekly Ixabepilone (BMS 247550) in Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Lapatinib and Ixabepilone in Treating Patients With Advanced Solid Tumors
Phase I Study of Lapatinib (GW572016) in Combination With Weekly Ixabepilone (BMS 247550) in Advanced Solid Tumors
Status: Archived
USC Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Lapatinib and Ixabepilone in Treating Patients With Advanced Solid Tumors
Phase I Study of Lapatinib (GW572016) in Combination With Weekly Ixabepilone (BMS 247550) in Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
USC Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Lapatinib and Ixabepilone in Treating Patients With Advanced Solid Tumors
Phase I Study of Lapatinib (GW572016) in Combination With Weekly Ixabepilone (BMS 247550) in Advanced Solid Tumors
Status: Archived
University of California Davis Cancer Center
mi
from
Sacramento, CA
Lapatinib and Ixabepilone in Treating Patients With Advanced Solid Tumors
Phase I Study of Lapatinib (GW572016) in Combination With Weekly Ixabepilone (BMS 247550) in Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
University of California Davis Cancer Center
mi
from
Sacramento, CA
Lapatinib and Ixabepilone in Treating Patients With Advanced Solid Tumors
Phase I Study of Lapatinib (GW572016) in Combination With Weekly Ixabepilone (BMS 247550) in Advanced Solid Tumors
Status: Archived
Louisiana State University Health Sciences Center
mi
from
Shreveport, LA
Lapatinib and Ixabepilone in Treating Patients With Advanced Solid Tumors
Phase I Study of Lapatinib (GW572016) in Combination With Weekly Ixabepilone (BMS 247550) in Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Louisiana State University Health Sciences Center
mi
from
Shreveport, LA
Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) in Patients With Metastatic or Locally Advanced Ovarian Cancer
A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 When Given on a Q14 Day or a Q21 Day Schedule in Patients With Metastatic or Locally Advanced Platinum-Resistant Ovarian Cancer
Status: Archived
USC Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) in Patients With Metastatic or Locally Advanced Ovarian Cancer
A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 When Given on a Q14 Day or a Q21 Day Schedule in Patients With Metastatic or Locally Advanced Platinum-Resistant Ovarian Cancer
Status: Archived
Updated: 1/1/1970
USC Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) in Patients With Metastatic or Locally Advanced Ovarian Cancer
A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 When Given on a Q14 Day or a Q21 Day Schedule in Patients With Metastatic or Locally Advanced Platinum-Resistant Ovarian Cancer
Status: Archived
Gynecologic Oncology Associates
mi
from
Newport Beach, CA
Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) in Patients With Metastatic or Locally Advanced Ovarian Cancer
A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 When Given on a Q14 Day or a Q21 Day Schedule in Patients With Metastatic or Locally Advanced Platinum-Resistant Ovarian Cancer
Status: Archived
Updated: 1/1/1970
Gynecologic Oncology Associates
mi
from
Newport Beach, CA
Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) in Patients With Metastatic or Locally Advanced Ovarian Cancer
A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 When Given on a Q14 Day or a Q21 Day Schedule in Patients With Metastatic or Locally Advanced Platinum-Resistant Ovarian Cancer
Status: Archived
Palm Beach Cancer Institute - West Palm Beach
mi
from
West Palm Beach, FL
Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) in Patients With Metastatic or Locally Advanced Ovarian Cancer
A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 When Given on a Q14 Day or a Q21 Day Schedule in Patients With Metastatic or Locally Advanced Platinum-Resistant Ovarian Cancer
Status: Archived
Updated: 1/1/1970
Palm Beach Cancer Institute - West Palm Beach
mi
from
West Palm Beach, FL
Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) in Patients With Metastatic or Locally Advanced Ovarian Cancer
A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 When Given on a Q14 Day or a Q21 Day Schedule in Patients With Metastatic or Locally Advanced Platinum-Resistant Ovarian Cancer
Status: Archived
Piedmont Hematology Oncology
mi
from
Winston-Salem, NC
Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) in Patients With Metastatic or Locally Advanced Ovarian Cancer
A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 When Given on a Q14 Day or a Q21 Day Schedule in Patients With Metastatic or Locally Advanced Platinum-Resistant Ovarian Cancer
Status: Archived
Updated: 1/1/1970
Piedmont Hematology Oncology
mi
from
Winston-Salem, NC
Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) in Patients With Metastatic or Locally Advanced Ovarian Cancer
A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 When Given on a Q14 Day or a Q21 Day Schedule in Patients With Metastatic or Locally Advanced Platinum-Resistant Ovarian Cancer
Status: Archived
Sarah Cannon Cancer Center
mi
from
Nashville, TN
Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) in Patients With Metastatic or Locally Advanced Ovarian Cancer
A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 When Given on a Q14 Day or a Q21 Day Schedule in Patients With Metastatic or Locally Advanced Platinum-Resistant Ovarian Cancer
Status: Archived
Updated: 1/1/1970
Sarah Cannon Cancer Center
mi
from
Nashville, TN
Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome
Phase II Study of Combination of Thymoglobulin, Cyclosporine, Methylprednisone, and GCSF in Patients With Newly Diagnosed Aplastic Anemia or With Hypoplastic or Low/Intermediate-1 Risk Myelodysplastic Syndrome
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome
Phase II Study of Combination of Thymoglobulin, Cyclosporine, Methylprednisone, and GCSF in Patients With Newly Diagnosed Aplastic Anemia or With Hypoplastic or Low/Intermediate-1 Risk Myelodysplastic Syndrome
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies
Status: Archived
University of Michigan Health Systems
mi
from
Ann Arbor, MI
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies
Status: Archived
Updated: 1/1/1970
University of Michigan Health Systems
mi
from
Ann Arbor, MI
Phase I Targeting Dominant Intraprostatic Lesion Using MR Spectroscopy and HDR Brachytherapy
Phase I Study of Targeting Dominant Intraprostatic Lesion Using Functional MR Spectroscopy and High Dose Rate Brachytherapy
Status: Archived
Unversity of California, San Francisco
mi
from
San Francisco, CA
Phase I Targeting Dominant Intraprostatic Lesion Using MR Spectroscopy and HDR Brachytherapy
Phase I Study of Targeting Dominant Intraprostatic Lesion Using Functional MR Spectroscopy and High Dose Rate Brachytherapy
Status: Archived
Updated: 1/1/1970
Unversity of California, San Francisco
mi
from
San Francisco, CA
Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY
Trial of Allogeneic BMT for Hematologic Malignancies Using HLA-matched Related or Unrelated Donors With Fludarabine and IV Busulfan as Pre-transplant Conditioning Followed by Post-transplant Immunosuppression With High-dose Cyclophosphamide
Status: Archived
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY
Trial of Allogeneic BMT for Hematologic Malignancies Using HLA-matched Related or Unrelated Donors With Fludarabine and IV Busulfan as Pre-transplant Conditioning Followed by Post-transplant Immunosuppression With High-dose Cyclophosphamide
Status: Archived
Updated: 1/1/1970
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY
Trial of Allogeneic BMT for Hematologic Malignancies Using HLA-matched Related or Unrelated Donors With Fludarabine and IV Busulfan as Pre-transplant Conditioning Followed by Post-transplant Immunosuppression With High-dose Cyclophosphamide
Status: Archived
Marcos deLima, MD
mi
from
Houston, TX
Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY
Trial of Allogeneic BMT for Hematologic Malignancies Using HLA-matched Related or Unrelated Donors With Fludarabine and IV Busulfan as Pre-transplant Conditioning Followed by Post-transplant Immunosuppression With High-dose Cyclophosphamide
Status: Archived
Updated: 1/1/1970
Marcos deLima, MD
mi
from
Houston, TX
Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY
Trial of Allogeneic BMT for Hematologic Malignancies Using HLA-matched Related or Unrelated Donors With Fludarabine and IV Busulfan as Pre-transplant Conditioning Followed by Post-transplant Immunosuppression With High-dose Cyclophosphamide
Status: Archived
Paul V. O'Donnell, M.D., Ph.D.
mi
from
Seattle, WA
Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY
Trial of Allogeneic BMT for Hematologic Malignancies Using HLA-matched Related or Unrelated Donors With Fludarabine and IV Busulfan as Pre-transplant Conditioning Followed by Post-transplant Immunosuppression With High-dose Cyclophosphamide
Status: Archived
Updated: 1/1/1970
Paul V. O'Donnell, M.D., Ph.D.
mi
from
Seattle, WA